Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Other Gross PP&E Adjustments: 2009-2025

Historic Other Gross PP&E Adjustments for Northwest Biotherapeutics (NWBO) over the last 12 years, with Sep 2025 value amounting to $19.7 million.

  • Northwest Biotherapeutics' Other Gross PP&E Adjustments rose 8.74% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year increase of 6.00%. This contributed to the annual value of $17.6 million for FY2024, which is 3.60% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Other Gross PP&E Adjustments stood at $19.7 million for Q3 2025, which was up 3.60% from $19.0 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Other Gross PP&E Adjustments peaked at $19.7 million during Q3 2025, and registered a low of -$5.1 million during Q1 2021.
  • Over the past 3 years, Northwest Biotherapeutics' median Other Gross PP&E Adjustments value was $17.6 million (recorded in 2024), while the average stood at $17.1 million.
  • The largest annual percentage gain for Northwest Biotherapeutics' Other Gross PP&E Adjustments in the last 5 years was 516.71% (2021), contrasted with its biggest fall of 20.56% (2021).
  • Northwest Biotherapeutics' Other Gross PP&E Adjustments (Quarterly) stood at $11.2 million in 2021, then grew by 2.49% to $11.5 million in 2022, then spiked by 47.39% to $17.0 million in 2023, then rose by 3.60% to $17.6 million in 2024, then grew by 8.74% to $19.7 million in 2025.
  • Its Other Gross PP&E Adjustments stands at $19.7 million for Q3 2025, versus $19.0 million for Q2 2025 and $18.1 million for Q1 2025.